{
    "Variants Include": [
        {
            "Gene": "PARK2",
            "variants": [
                {
                    "HGVS": "N.D. (No specific HGVS nomenclature provided in the literature. Standardization via API requires specific nucleotide changes which are not given)",
                    "cDNA Change": {
                        "transcript": "N.D.",
                        "ref": "N.D.",
                        "alt": "N.D.",
                        "position": "N.D."
                    },
                    "Protein Change": {
                        "ref": "N.D.",
                        "alt": "N.D.",
                        "position": "N.D."
                    },
                    "Description in input context": "Somatic PARK2 mutations in cancer occur in the same domains as the germline PD mutations. Two residues, Arg42 and Arg275, are mutated both in colon cancer and GBM and in PD, but the resultant amino acids differ between the somatic cancer mutations and the germline PD mutations. Other mutations include Ile2 and E344G."
                }
            ]
        }
    ],
    "Described Disease": {
        "Described Disease": "Glioblastoma multiforme, Colon cancer, Lung cancer",
        "MONDO": "MONDO:0002673 (Glioblastoma multiforme), MONDO:0004973 (Colorectal cancer, which can be related to colon cancer), MONDO:0005011 (Lung cancer). Retrieved from MONDO database."
    },
    "Experiment Method": [
        {
            "Assay Method": "Array comparative genomic hybridization (aCGH)",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Colon tumor samples, GBM samples",
                "Description": "Colon tumor samples (n=98) from the Memorial Sloan - Kettering Cancer Center and GBMs (n = 216) as part of the TCGA initiative were used. Source DNAs were extracted from primary tumors for the aCGH study."
            },
            "Readout type": "N.D. (Not clear if qualitative or quantitative from the given text)",
            "Readout description": [
                {
                    "Variant": "N.D.",
                    "Conclusion": "N.D.",
                    "Molecular Effect": "N.D.",
                    "Result Description": "In GBM samples, 85% (53 out of 62) of samples with loss on 6q showed loss of the PARK2 gene within the area of CNA. In colon cancer samples, 100% (24 out of 24) of samples with loss on 6q showed loss of PARK2 within the CNA region."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "Analysis of data for the CNAs observed was performed using the RAE method. The status of genomic loss at the PARK2 locus in colon cancer samples was assigned as either likely heterozygous loss (D0 ≥ 0.9) or homozygous deletion (D0 ≥ 0.9 and D1 ≥ 0.5), and in GBM as previously described per the multicomponent model in RAE."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D. (Based on general knowledge, normal copy number would imply no loss at the PARK2 locus, but not clearly defined in literature)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Likely heterozygous loss (D0 ≥ 0.9) or homozygous deletion (D0 ≥ 0.9 and D1 ≥ 0.5) at the PARK2 locus in colon cancer samples; as previously described per the multicomponent model in RAE for GBM",
                "Source": "Literature"
            },
            "Approved assay": {
                "Approved assay": "Yes (aCGH is a commonly used method for studying copy number alterations in cancers)"
            }
        },
        {
            "Assay Method": "PCR amplification and sequencing",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Genomic DNA from primary tumors and normal tissue of the same individual",
                "Description": "Exonic regions for the PARK2 gene were amplified from 10 ng of whole - genome amplified DNA (REPLI - g Midi, Qiagen) as a template using specific primers designed for 16 amplicons of 500 bp or less."
            },
            "Readout type": "Qualitative (detecting presence or absence of mutations)",
            "Readout description": [
                {
                    "Variant": "N.D.",
                    "Conclusion": "N.D.",
                    "Molecular Effect": "N.D.",
                    "Result Description": "Somatic mutations in PARK2 were identified in human cancers. Whenever a presumptive mutation was identified in a primary tumor, it was verified that the change did not correspond to a known SNP and was somatically acquired by examining the sequence of the gene in genomic DNA from normal tissue of the same individual."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "Yes",
                "Description": "All putative mutations were confirmed by a second PCR and sequencing reaction."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "No mutation detected in normal tissue DNA",
                "Source": "Literature"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Mutation detected in primary tumor DNA that is not a known SNP and is somatically acquired",
                "Source": "Literature"
            },
            "Approved assay": {
                "Approved assay": "Yes (PCR amplification and sequencing are standard methods for mutation detection)"
            }
        },
        {
            "Assay Method": "Cell culture",
            "Material used": {
                "Material Source": "Cell line",
                "Material Name": "T98G, DBTRG, RKO, H441, H358, HEK 293T",
                "Description": "All cell lines were obtained from American Type Tissue Culture and cultured using the recommended media (Invitrogen) + 10% FBS (Invitrogen) and penicillin plus streptomycin at 37 °C in 5% CO2. HEK 293T cells were cultured in Dulbecco's modified eagle's medium (DMEM) + 10% FBS (Invitrogen)."
            },
            "Readout type": "N.D. (Depends on subsequent assays performed on these cells)",
            "Readout description": [
                {
                    "Variant": "N.D.",
                    "Conclusion": "N.D.",
                    "Molecular Effect": "N.D.",
                    "Result Description": "Transfection of WT PARK2 into human cancer cell lines lacking PARK2 protein expression potently inhibited colony - forming activity. Expression of PARK2 with tumor - derived mutations resulted in substantially decreased colony - forming activity as compared to WT PARK2. Transfection of WT but not mutant PARK2 into cells from the DBTRG line resulted in a reduction in the rate of cell growth. WT PARK2 decreased tumor growth in vivo, a property that was reduced by the cancer - specific mutations."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "Yes",
                "Description": "All experiments were performed in triplicate."
            },
            "Technical replicates": {
                "Technical replicates": "Yes",
                "Description": "All experiments were performed in triplicate."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "Two - tailed Student's t - test analysis was performed using GraphPad Prism software for some experiments. ANOVA was used for some comparisons as well."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D. (Based on general cell growth knowledge, normal cell growth rate without significant inhibition for untransfected cells, but not clearly defined in literature)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Significant reduction in colony - forming activity, cell growth rate or in vivo tumor growth for cells transfected with mutant PARK2 compared to WT PARK2 as determined by statistical analysis",
                "Source": "Literature"
            },
            "Approved assay": {
                "Approved assay": "Yes (Cell culture is a fundamental method in cancer research)"
            }
        },
        {
            "Assay Method": "Protein blot, immunoprecipitation and immunostaining",
            "Material used": {
                "Material Source": "Cell line",
                "Material Name": "Cells from various cell lines (e.g., T98G)",
                "Description": "Protein blot analysis was performed using standard methods. Antibodies against various epitopes and proteins were used. Immunoprecipitation was performed using the Flag immunoprecipitation kit. In vivo and in vitro ubiquitination assays were performed as per manufacturer's protocols. Immunostaining was performed with specific antibodies."
            },
            "Readout type": "Qualitative/Quantitative (Protein presence/absence can be qualitative, and densitometry for quantitation)",
            "Readout description": [
                {
                    "Variant": "N.D.",
                    "Conclusion": "N.D.",
                    "Molecular Effect": "N.D.",
                    "Result Description": "Cancer - specific mutations in PARK2 were found to substantially compromise the association of PARK2 with ubiquitinated target proteins in cancer cells. The mutations appeared to substantially decrease, but not completely abolish, the E3 ligase function. All PARK2 cancer mutations analyzed resulted in a decreased ability of PARK2 to interact with cyclin E. PARK2 mutations did not alter the protein's ability to regulate phosphorylation of c - Jun."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "For quantitation of cyclin E binding efficiency by densitometry, P < 0.05 (Student's t - test) for each mutant versus WT."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D. (Based on general knowledge, normal protein - protein interaction and ubiquitination levels, but not clearly defined in literature)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Substantial compromise in PARK2 - ubiquitinated target protein association, decreased ability to interact with cyclin E as determined by statistical analysis",
                "Source": "Literature"
            },
            "Approved assay": {
                "Approved assay": "Yes (Protein blot, immunoprecipitation and immunostaining are common methods in molecular biology and cancer research)"
            }
        },
        {
            "Assay Method": "Knockdown of PARK2",
            "Material used": {
                "Material Source": "Cell line",
                "Material Name": "Four cancer cell lines that show PARK2 expression",
                "Description": "PARK2 siRNAs were obtained from Invitrogen and cells were transfected using Lipofectamine RNAiMAX system."
            },
            "Readout type": "Qualitative/Quantitative (Protein level changes can be both qualitative and quantitative)",
            "Readout description": [
                {
                    "Variant": "N.D.",
                    "Conclusion": "N.D.",
                    "Molecular Effect": "N.D.",
                    "Result Description": "Knockdown of PARK2 with two independent short interfering RNAs (siRNAs), but not with scrambled - sequence siRNAs, resulted in an accumulation of cyclin E levels. PARK2 knockdown increased the proportion of cells in the S and the G2 - M phases. Immunofluorescence staining showed a significant increase in the frequency of multipolar spindles and abnormal mitoses. PARK2 knockdown cells showed a marked increase in nuclear atypia characterized by micronuclei."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "Yes",
                "Description": "Scrambled - sequence siRNAs were used as negative controls."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D. (Based on general knowledge, normal cyclin E levels, cell cycle distribution and normal mitosis, but not clearly defined in literature)",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Accumulation of cyclin E levels, increased proportion of cells in S and G2 - M phases, significant increase in multipolar spindles, abnormal mitoses and nuclear atypia",
                "Source": "Literature"
            },
            "Approved assay": {
                "Approved assay": "Yes (RNAi - mediated knockdown is a common method to study gene function in cancer cells)"
            }
        },
        {
            "Assay Method": "Retrovirus production",
            "Material used": {
                "Material Source": "Cell line",
                "Material Name": "HEK 293T cells",
                "Description": "HEK 293T cells were seeded in 10 - cm - diameter dishes and co - transfected with pE - ampho vector and pQCXIP - PARK2 (WT or mutants) using Lipofectamine. Retroviral particles were collected, filtered and used to infect cells."
            },
            "Readout type": "N.D. (Depends on subsequent assays on infected cells)",
            "Readout description": [
                {
                    "Variant": "N.D.",
                    "Conclusion": "N.D.",
                    "Molecular Effect": "N.D.",
                    "Result Description": "Retroviral particles were used to infect cells for subsequent experiments such as studying the effect of PARK2 (WT or mutants) on cell growth and other phenotypes."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical